# US 2023/0407251 A1 · Composition and methods of genome editing of b-cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0407251 A1
- Document ID: US20230407251A1
- Status: Published application
- Kind: A1
- Application number: 18/141,278
- Filed: 2023-04-28
- Published: 2023-12-21
- Earliest claimed: 2015-04-03
- Assignees: Dana-Farber Cancer Institute, Inc.
- Applicants: Dana-Farber Cancer Institute, Inc.
- Inventors: Micheal Goldberg; Vera Greiner
- Web page: https://patentgrep.com/patent/US20230407251A1

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- A61K 40/13: B-cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/4232: {Tumor necrosis factors [TNF] or CD70}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 19/10: for osteoporosis
- A61P 27/02: Ophthalmic agents
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 5/0635: {B lymphocytes}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/907: {in mammalian cells}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2501/48: Regulators of apoptosis
- C12N 2510/02: Cells for production
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides methods compositions and methods of preparing autologous (or allogeneic) B cells that secrete a monoclonal of interest useful in immunotherapy or B cells with an altered function.

## Claims

### Claim at position 1

1-52. (canceled)

### Claim 53

A primary human B cell that produces a heterologous therapeutic antibody, comprising the primary human B cell with variable regions of light and heavy chains of an endogenous B cell receptor substituted with variable regions of heterologous light and heavy chains of the heterologous therapeutic antibody.

### Claim 54 (depends on 53)

The primary human B cell of claim 53, wherein the primary human B cell is a transfected cell.

### Claim 55 (depends on 54)

The primary human B cell of claim 54, wherein the primary human B cell is transfected with the variable regions of the heterologous light and heavy chains of the heterologous therapeutic antibody.

### Claim 56 (depends on 55)

The primary human B cell of claim 55, wherein substitution of the light and heavy chains of the endogenous B cell receptor is accomplished using an engineered nuclease.

### Claim 57 (depends on 53)

The primary human B cell of claim 53, wherein the therapeutic monoclonal antibody is specific for TNF-α, IGHE, IL-1, IL-1p, IL-2, IL-4, IL-5, IL-6, IL-6R, IL-9, IL-13, IL-17A, IL-20, IL-22, IL-23, IL-25, BAFF, RANKL, integrin-α4, IL-6R, VEGF-A, VEGFR1, VEGFR2, EGFR, HER2, HER3, CA125, integrin α4β7, integrin α7β7, interferon α/β receptor, CXCR4, CD2, CD3, CD4, CD5, CD6, CD19, CD20, CD22, CD23, CD25, CD27, CD28, CD30, CD33, CD37, CD38, CD40, CD41, CD44, CD51, CD52, CD56, CD70, CD74, CD79B, CD80, CD125, CD137, CD140a, CD147, CD152, CD154, CD200, CD221, CCR4, CCR5, gp120, angiopoietin 3, PCSK9, HNGF, HGF, GD2, GD3, C5, FAP, ICAM-1, LFA-1, interferon alpha, interferon gamma, interferon gamma-induced protein, SLAMF7, HHGFR, TWEAK receptor, NRP1, EpCAM, CEA, CEA-related antigen mesothelin, MUC1, IGF-1R, TRAIL-R2, DR5, DLL4, VWF, MCP-1, β-amyloid, phosphatidyl serine, Rhesus factor, CCL11, NARP-1, RTN4, ACVR2B, SOST, NOGO-A, sclerostin, avian influenza, influenza A hemagglutinin, hepatitis A virus, hepatitis B virus, hepatitis C virus, respiratory syncytial virus, rabies virus glycoprotein, cytomegalovirus glycoprotein B, Tuberculosis, Ebola, Staphylococcus aureus, SARS, MERS, malaria, HPV, HSV, TGF-β, TGF-βR1, NGF, LTA, AOC3, ITGA2, GM-CSF, GM-CSF receptor, oxLDL, LOXL2, RON, KIR2D, PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, BTLA, episialin, myostatin, or HIV-1.

### Claim 58 (depends on 53)

The primary human B cell of claim 53, wherein the primary human B cell can be administered to a patient.

### Claim 59 (depends on 53)

A method for immunotherapy, comprising administering the primary human B cells of claim 53 to a patient.

### Claim 60

A population of modified primary human B cells, comprising a population of primary B cells that has been gene-edited to substitute variable regions of the light and heavy chains of an endogenous B cell receptor with variable regions of light and heavy chains of a heterologous antibody.

### Claim 61 (depends on 60)

The population of modified primary human B cells of claim 60, wherein the population of primary human B cells comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10% gene-edited cells.

### Claim 62 (depends on 60)

The population of modified primary human B cells of claim 60, wherein the population of primary B cells is transfected.

### Claim 63 (depends on 60)

The population of modified primary human B cells of claim 60, wherein the primary B cells are activated prior to transfection.

### Claim 64 (depends on 60)

The population of modified primary human B cells of claim 60, wherein the primary B cells are cultured in IL4 before or after transfection.

### Claim 65 (depends on 62)

The population of modified primary human B cells of claim 62, wherein viability of the population of primary B cells after transfection is at least 50, 60, 70, 75 or 80%.

### Claim 66 (depends on 60)

The primary human B cell of claim 60, wherein the therapeutic monoclonal antibody is specific for TNF-α, IGHE, IL-1, IL-1p, IL-2, IL-4, IL-5, IL-6, IL-6R, IL-9, IL-13, IL-17A, IL-20, IL-22, IL-23, IL-25, BAFF, RANKL, integrin-α4, IL-6R, VEGF-A, VEGFR1, VEGFR2, EGFR, HER2, HER3, CA125, integrin α4β7, integrin α7β7, interferon α/β receptor, CXCR4, CD2, CD3, CD4, CD5, CD6, CD19, CD20, CD22, CD23, CD25, CD27, CD28, CD30, CD33, CD37, CD38, CD40, CD41, CD44, CD51, CD52, CD56, CD70, CD74, CD79B, CD80, CD125, CD137, CD140a, CD147, CD152, CD154, CD200, CD221, CCR4, CCR5, gp120, angiopoietin 3, PCSK9, HNGF, HGF, GD2, GD3, C5, FAP, ICAM-1, LFA-1, interferon alpha, interferon gamma, interferon gamma-induced protein, SLAMF7, HHGFR, TWEAK receptor, NRP1, EpCAM, CEA, CEA-related antigen mesothelin, MUC1, IGF-1R, TRAIL-R2, DR5, DLL4, VWF, MCP-1, β-amyloid, phosphatidyl serine, Rhesus factor, CCL11, NARP-1, RTN4, ACVR2B, SOST, NOGO-A, sclerostin, avian influenza, influenza A hemagglutinin, hepatitis A virus, hepatitis B virus, hepatitis C virus, respiratory syncytial virus, rabies virus glycoprotein, cytomegalovirus glycoprotein B, Tuberculosis, Ebola, Staphylococcus aureus, SARS, MERS, malaria, HPV, HSV, TGF-β, TGF-βR1, NGF, LTA, AOC3, ITGA2, GM-CSF, GM-CSF receptor, oxLDL, LOXL2, RON, KIR2D, PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, BTLA, episialin, myostatin, or HIV-1.

### Claim 67 (depends on 60)

The population of primary human B cells of claim 60, wherein the population can be administered to a patient.

### Claim 68 (depends on 60)

A method for immunotherapy, comprising administering the population of modified primary human B cells of claim 60 to a patient.
